JPRN-jRCT2080220386未知1 期
Clinical Evaluation of Lapatinib Administered with Capecitabine in Japanese Patients with ErbB2 Overexpressing Advanced or Metastatic Breast Cancer
GlaxoSmithKline K.K.0 个研究点目标入组 50 人开始时间: 2007年4月27日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •- Signed informed consent
- •- ErbB2 overexpressing advanced or metastatic breast cancer
- •- Prior treatments with taxanes, anthracyclines, trastuzumab
- •- No prior treatment with capecitabine
- •- Female 20 years of age
- •- ECOG Performance Status of 0 or 1
- •- Cardiac ejection fraction within the institutional range of normal
- •- Adequate hematologic value, hepatic and renal function
- •- Pregnant or lactating females
- •- Conditions affecting the absorption of oral drugs
- •- History of other malignancy
- •- Known history of uncontrolled or symptomatic angina, arrhythmia or congestive heart failure
- •- Known history or clinical evidence of leptomeningeal carcinomatosis
- •- Known dihydropyrimidine dehydrogenase (DPD) deficiency
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
1 期
Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ. - Pre-operative study of Lapatanib in DCISWomen with a core biopsy diagnosis of histologically proven Her2 positive DCIS (or DCIS and invasive cancer). Women undergoing re-excision of DCIS will be eligible provided residual DCIS is present in the re-excision specimen.MedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2006-006619-64-GBniversity Hospital of South Manchester NHS Foundation Trust80
进行中（未招募）
不适用
INVESTIGATION OF THE EFFICACY OF LAPATINIB MONOTHERAPY AND TEMOZOLOMIDE PLUS LAPATINIB COMBINATION, IN RECURRENT HIGH GRADE GLIOMAS. A PHASE I/II STUDY. - N/ARefractory glioblastoma multiforme.EUCTR2007-006656-19-GRHellenic Cooperative Oncology Group
进行中（未招募）
不适用
Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancerRectal cancer stage IIRectal cancer stage IIIMedDRA version: 16.1Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001203-36-PTInstituto Português de Oncologia do Porto Francisco Gentil, EPE
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20